ArticleMycotoxin research2025
Dietary melegueta seed powder modulates growth, hepatic function, and biomarkers to counteract aflatoxin B₁ toxicity in broilers.
Article in Mycotoxin research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Dietary Melegueta pepper alleviates heat stress-induced disruptions in haematobiochemical parameters, liver histopathology and growth performance indices of broiler chickens in tropical conditions.Tropical animal health and production · 2026Article
- Dietary melegueta seed powder modulates growth, hepatic function, and biomarkers to counteract aflatoxin B₁ toxicity in broilers.Mycotoxin research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aframomum melegueta seed powder (AMSP) is a phytogenic supplement with notable antioxidant and anti-inflammatory properties. This study assessed its potential to protect broiler chickens against aflatoxin B₁ (AFB₁)-induced toxicity. AMSP was screened for phytochemicals and antioxidant activity. A total of 320 Cobb 500 chicks were assigned to four diets using a completely randomized design: CTRL (control), ATB1 (0.4 mg/kg AFB₁), A1AF (AFB₁ + 0.5 g/kg AMSP), and A2AF (AFB₁ + 1.0 g/kg AMSP) for six weeks. Exposure to AFB₁ by the birds in ATB1 markedly (P < 0.05) impaired growth performance, as evidenced by reduced final body weight (2,315.82 g vs. 2,743.23 g in CTRL), lower protein intake (813.45 g vs. 837.24 g), and increased feed conversion ratio (1.70 vs. 1.47). AMSP supplementation, particularly at 1.0 g/kg in A2AF, restored growth performance to control levels, while supplementation at 0.5 g/kg in A1AF achieved partial recovery. Compared with the CTRL group, AFB₁ exposure in the ATB1 birds reduced (P < 0.05) packed cell volume (29.37% vs. 35.05%) and haemoglobin concentration (9.79 g/dL vs. 11.68 g/dL), elevated (P < 0.05) ALT (24.04 vs. 16.77 IU/L), AST (70.62 vs. 57.59 IU/L), creatinine (74.85 vs. 52.43 µmol/L), TNF-α, IL-6, and corticosterone, and suppressed (P < 0.05) IL-10. These disruptions were largely normalised by AMSP, especially at 1.0 g/kg, restoring ALT, AST, creatinine, IL-10, and corticosterone to CTRL values. Histopathological analysis further confirmed that periportal inflammation and hepatic architectural damage induced by AFB₁ in ATB1 were attenuated in A1AF and absent in A2AF. In conclusion, AMSP supplementation at 1.0 g/kg effectively mitigated AFB₁-induced growth, biochemical, and hepatic impairments in broilers. These findings highlight AMSP as a promising natural feed additive for improving poultry health and ensuring feed safety, warranting further investigation into its application under commercial production conditions.
Indexed as
Identifiers
41351642What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.